Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial | Reuters

Oct 1 Ardelyx Inc said its experimental

drug to treat constipation-related irritable bowel syndrome

achieved the main goal of increasing bowel movement compared to

a placebo in a mid-stage study involving 371 patients.

Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc

in October 2012.

The companies are also testing the drug for two

kidney-related indications.



(Reporting by Amrutha Penumudi in Bangalore; Editing by Ted

Kerr)

Know more here.